# I Blood Group System

### Number of antigens 1

High prevalence I

## **Terminology**

ISBT symbol (number) I (27)

Obsolete names 207; Ii collection

History The I antigen was placed in a system in 2002,

when mutations of the *I* gene encoding the glycosyltransferase responsible for converting i-active straight oligosaccharide chains to I-active

branched chains were identified.

# **Expression**

Soluble form Human milk, saliva, amniotic fluid, urine, ovarian

cyst fluid (small amounts in serum/plasma)

Other blood cells Lymphocytes, monocytes, granulocytes, platelets

Tissues Wide tissue distribution

#### Gene

Chromosome 6p24.2

Name I(GCNT2, IGnT)

Organization 3 exons spread over approximately 100 kbp of


gDNA; three forms of exon 1 are differentially spliced to give one of three transcripts: IGnTA,

IGnTB or IGnTC<sup>1,2,3</sup>

Product 6-β-N-acetylglucosaminyltransferase (β6GlcNAc-

transferase,  $\beta$ 6GlcNAc-T); the branching enzyme for I antigen expression on RBCs is encoded by *IGnTC*; expression of I antigen on lens epithelium is

encoded by IGnTB



#### **Database accession numbers**

GenBank NM\_145655.3; AF458026 (mRNA)

Entrez Gene ID 2651

### Molecular bases of weak I antigen

Homozygosity or compound heterozygosity for weakened expression of *GCNT2* alleles leads to the I+<sup>W</sup> phenotype. The reference allele, *GCNT2\*01* (Accession number NM\_145655.3) encodes I (I1). Nucleotide differences from this allele, and amino acids affected, are given.

| Allele<br>encodes | Allele name  | Exon | Nucleotide | Amino acid | Ethnicity (prevalence)             |
|-------------------|--------------|------|------------|------------|------------------------------------|
| I+W               | GCNT2*01W.01 | 1C   | 243T>A     | Asn81Lys   | Caucasians,<br>Taiwanese<br>(Rare) |
| I+W               | GCNT2*01W.02 | 1C   | 505G>A     | Ala169Thr  | Caucasians<br>(Rare)               |
| I+W               | GCNT2*01W.03 | 1C   | 683G>A     | Arg228Gln  | Caucasians (Rare)                  |

# Molecular bases of silencing of GCNT2

Homozygosity or compound heterozygosity for silent *GCNT2* alleles leads to the I– (adult i) phenotype. Differences from *GCNT2\*01* reference allele (accession number NM 145655.3) are given.

| Allele name  | Exon            | Nucleotide                | Amino acid              | Ethnicity<br>(prevalence)            |
|--------------|-----------------|---------------------------|-------------------------|--------------------------------------|
| GCNT2*01N.01 | 3               | 1049G>A                   | Gly350Glu               | Japanese, Taiwanese<br>(Rare)        |
| GCNT2*01N.02 | 3               | 1154G>A                   | Arg385His               | Japanese, Taiwanese<br>(Rare)        |
| GCNT2*01N.04 | 1C<br>2         | 816G>C;<br>1006G>A        | Glu272Asp;<br>Gly336Arg | (Rare)                               |
| GCNT2*01N.05 | 2               | 984G>A                    | Trp328Stop              | Arabs (Rare)                         |
| GCNT2*01N.06 | 1B, 1C,<br>2, 3 | del exons<br>1B, 1C, 2, 3 | No protein              | Taiwanese (Rare)<br>Pakistani (Rare) |
| GCNT2*01N.07 | 1C              | 651delA                   | Val244Stop              | Japanese (Rare)                      |
| GCNT2*01N.08 | 2               | 935G>A                    | Gly312Asp               | Persian Jews (Rare)                  |

# Amino acid sequence for IGnTC $\beta$ 6GlcNAc-transferase<sup>1,2,3</sup>

| MNFWRYCFFA | FTLLSVVIFV | RFYSSQLSPP | KSYEKLNSSS | ERYFRKTACN | 50  |
|------------|------------|------------|------------|------------|-----|
| HALEKMPVFL | WENILPSPLR | SVPCKDYLTQ | NHYITSPLSE | EEAAFPLAYV | 100 |
| MVIHKDFDTF | ERLFRAIYMP | QNVYCVHVDE | KAPAEYKESV | RQLLSCFQNA | 150 |
| FIASKTESVV | YAGISRLQAD | LNCLKDLVAS | EVPWKYVINT | CGQDFPLKTN | 200 |
| REIVQHLKGF | KGKNITPGVL | PPDHAIKRTK | YVHQEHTDKG | GFFVKNTNIL | 250 |
| KTSPPHQLTI | YFGTAYVALT | REFVDFVLRD | QRAIDLLQWS | KDTYSPDEHF | 300 |
| WVTLNRVSGV | PGSMPNASWT | GNLRAIKWSD | MEDRHGGCHG | HYVHGICIYG | 350 |
| NGDLKWLVNS | PSLFANKFEL | NTYPLTVECL | ELRHRERTLN | QSETAIQPSW | 400 |
| YF         |            |            |            |            | 402 |

#### Carrier molecule

The *GCNT*2 gene product adds  $\beta$ 6GlcNAc to i-active, linear oligosaccharide chains of repeating *N*-acetyllactosamine units on glycolipids and glycoproteins on RBCs, and to glycoproteins in plasma (see figure in Section III). Present on proteins with polylactosamine-containing N-glycans (band 3, glucose transporter, etc.)<sup>4</sup>.

A range of copy numbers per RBC has been reported<sup>4</sup>.

#### **Function**

Not known.

#### Disease association

A decreased expression of I antigen and concomitant increased expression of the reciprocal i antigen are associated with leukemia, Tk polyagglutination, thalassemia, sickle cell disease, HEMPAS, Diamond Blackfan anemia, myeloblastic erythropoiesis, sideroblastic erythropoiesis, and any condition that results in stress hematopoiesis. Congenital cataracts are associated with a lack or marked reduction of I antigen on RBCs and lens<sup>2</sup>. Caucasians without cataracts have a markedly reduced  $\beta$ 6GlcNAc-transferase activity<sup>1</sup>. Asians with cataracts have no  $\beta$ 6GlcNAc-transferase activity<sup>2,3</sup>. Anti-I is associated with cold hemagglutinin disease (CHAD) and pneumonia due to *Mycoplasma pneumoniae*.

## Phenotypes associated with I antigen and the reciprocal i antigen

| RBCs    | Antiger | Antigen expression |        |  |
|---------|---------|--------------------|--------|--|
|         | 1       | i                  |        |  |
| Adult   | Strong  | Weak               | Common |  |
| Cord    | Weak    | Strong             | All    |  |
| i Adult | Trace   | Strong             | Rare   |  |

#### Comments

I antigens occur at the branching points of A-, B-, and H-active oligosaccharide chains.

Branching is under developmental control regulated by phosphorylation of key residues in the C/EBP $\alpha$  transcription factor, which acts on the *GCNT2* promoter. Once the gene is activated, the level of the I antigen expression on RBCs of the newborn child begins to increase<sup>5</sup>.

#### References

- <sup>1</sup> Yu, L.-C., et al., 2001. Molecular basis of the adult i phenotype and the gene responsible for the expression of the human blood group I antigen. Blood 98, 3840–3845.
- <sup>2</sup> Yu, L.C., et al., 2003. The molecular genetics of the human I locus and molecular background explaining the partial association of the adult i phenotype with congenital cataracts. Blood 101, 2081–2087.

- $^3$  Inaba, N., et al., 2003. A novel I-branching  $\beta$ -1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression. Blood 101, 2870–2876.
- <sup>4</sup> Cooling, L., 2010. Polyactosamines, there's more than meets the "Ii:" a review of the I system. Immunohematology 26, 133–155.
- <sup>5</sup> Yu, L.C., Lin, M., 2011. Molecular genetics of the blood group I system and the regulation of I antigen expression during erythropoiesis and granulopoiesis. Curr Opin Hematol 18, 421–426.

# **I** Antigen

## **Terminology**

ISBT symbol (number) I1 (027001 or 27.1)

Obsolete names 900026; 207001; Individual

History Reported in 1956; named I to emphasize the high

degree of the "Individuality" of blood samples failing to react with a potent cold agglutinin. Placed in a collection with i antigen in 1990, and made a one-antigen system in 2002 when the gene encoding

the branching transferase was cloned.

#### **Occurrence**

Adults >99%

# **Reciprocal antigen**

i [See Ii Collection (207)].

# Expression

Cord RBCs Weaker than on adult RBCs; frequently appear to be

I-negative

Altered Weakened on RBCs produced under hematopoietic

stress, and on South East Asian ovalocytes (see also

Disease association).

# Molecular basis associated with I antigen

See System pages for molecular bases associated with I-negative (adult i) phenotype.

# Effect of enzymes and chemicals on I antigen on intact RBCs

Ficin/Papain Resistant (markedly enhanced)
Trypsin Resistant (markedly enhanced)
α-Chymotrypsin Resistant (markedly enhanced)

Sialidase Resistant (enhanced)

DTT 200 mM Resistant

Acid Resistant

### In vitro characteristics of anti-I

Immunoglobulin class IgM (rarely IgG)
Optimal technique RT or 4°C

Complement binding Yes; some hemolytic

# Clinical significance of anti-I

Transfusion reaction No (may need to infuse through an approved

blood warmer). Increased destruction of I+ RBCs transfused to people with the adult i phenotype and

alloanti-I

HDFN No

#### Autoanti-I

Most people have cold-reactive autoanti-I in their plasma.

A common specificity in CHAD and pregnancy.

#### Comments

So-called compound antigens have been described: IA, IB, IAB, IH, IP1,  $ILe^{bH}$ .

Alloanti-I is rare because the I– (adult i) phenotype is rare.